Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Income (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Net Income data on record, last reported at -$63.0 million in Q4 2025.

  • For Q4 2025, Net Income fell 36.79% year-over-year to -$63.0 million; the TTM value through Dec 2025 reached -$230.8 million, up 11.12%, while the annual FY2025 figure was -$230.8 million, 11.12% up from the prior year.
  • Net Income reached -$63.0 million in Q4 2025 per MRVI's latest filing, down from -$45.1 million in the prior quarter.
  • Across five years, Net Income topped out at $156.7 million in Q2 2022 and bottomed at -$172.5 million in Q3 2024.
  • Average Net Income over 5 years is $16.6 million, with a median of -$13.5 million recorded in 2023.
  • Peak YoY movement for Net Income: skyrocketed 9216.5% in 2021, then crashed 1582.49% in 2024.
  • A 5-year view of Net Income shows it stood at $127.1 million in 2021, then crashed by 31.22% to $87.4 million in 2022, then tumbled by 225.8% to -$110.0 million in 2023, then surged by 58.11% to -$46.1 million in 2024, then tumbled by 36.79% to -$63.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$63.0 million in Q4 2025, -$45.1 million in Q3 2025, and -$69.8 million in Q2 2025.